Sulbactam-durlobactam is the first pathogen-targeted therapy under investigation for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by ...

A research team has discovered a fundamental mechanism that helps the dreaded hospital pathogen Acinetobacter baumannii to survive. This mechanism explains why the pathogen is difficult to eradicate ...

Hospital-acquired infections are often hard to treat because the corresponding pathogens become increasingly resistant against antibiotics. The bacterium Acinetobacter baumannii is particularly feared ...

Credit: Getty Images. The investigational intravenous product is a combination of sulbactam, a β-lactam antibiotic, and durlobactam, a broad-spectrum β-lactamase inhibitor. The Food and Drug ...

In an effort to illustrate that genomic surveillance can build the foundation for scaleable precision phage therapy, an international collaboration analyzed the genomes of over 15,000 cases of ...

SHANGHAI and SAN FRANCISCO, May 18, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced dosing of the first Chinese ...

Credit: Getty Images. A PDUFA target date of May 29, 2023 has been set for the application. The Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee unanimously voted 12-0 in ...

Jaipur: A study conducted by SMS Medical College has raised alarm bells as it reveals a significant rise in antibiotic resistance among Acinetobacter bacteria infections. The research, which analysed ...

In a recent study published in Eurosurveillance, researchers investigated Acinetobacter species bloodstream infection (BSI) case counts from a subset of laboratory data continuously reported during ...

Dietary zinc deficiency promotes lung infection by Acinetobacter baumannii bacteria — a leading cause of ventilator-associated pneumonia, according to a new study published Nov. 15 in the journal ...